Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Imatinib is the standard first-line therapy for advanced gastrointestinal stromal tumor. (18)F-fluorodeoxyglucose PET computed tomography (FDG PET/CT) shows a faster response than computed tomography in nonpretreated patients.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Future Oncol

Title: Future oncology (London, England)

Publisher: Future Medicine Ltd

ISSN (Electronic): 1744-8301

ISSN (Print): 1479-6694

Publication date (Electronic): 2015

Volume: 11

Issue: 6

Affiliations

[1 ] Grupo Argentino de Tumores Estromales Digestivos (GATE-D), Buenos Aires 1426, Argentina.

Article

DOI: 10.2217/fon.14.292

PubMed ID: 25760976

SO-VID: 787c87f7-7f69-4c3c-9254-4dc9fe326bbb

History

Keywords: FDG,GIST,PET,assessment,early,imatinib 800 mg,metabolic

Data availability:

Keywords: FDG, GIST, PET, assessment, early, imatinib 800 mg, metabolic

Comments

Comment on this article

scite_

Cited by 4

See all cited by